Etanercept, Recombinant human TNFR, Fc tagged

Specification

• Cat#: THP-0112
• Product Name: Etanercept, Recombinant human TNFR, Fc tagged
• Description: Etanercept consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of the product contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. It encodes 934 amino acids, expressed in CHO Cells.
• Sequences: LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
• Species: Human
• Molecular Weight: 51234.9 Da
• Source: CHO
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: 185243-69-0
• Formula: C2224H3475N621O698S36
• Endotoxin Level: <0.001 EU per 1 μg of the peptide by the LAL method
• Biological Activity: 50mg/ml

Pharmaceutical Information

• Pharmaceutical Application: Etanercept
• Applications: The product is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. The product is also used to improve psoriatic arthritis and ankylosing spondylitis.
• Examples of Clinical Use: Active rheumatoid arthritis and plaque psoriasis
• Pharmacodynamics: The product binds specifically to tumor necrosis factor (TNF) and thereby modulates biological processes that are induced or regulated by TNF. Such processes or molecules affected include the level of adhesion molecules expressed, as well as serum levels of cytokines and matrix metalloproteinase-3, also known as stromelysin. In animal models, etanarcept has been demonstrated to affect inflammation, such as in murine collagen-induced arthritis.
• Mechanism of action: There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55). Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.
• Affected organisms: Humans and other mammals
• Targets: Target 1. Tumor necrosis factor; Target 2. Tumor necrosis factor receptor superfamily member 1B; Target 3. High affinity immunoglobulin gamma Fc receptor I; Target 4. Low affinity immunoglobulin gamma Fc region receptor III-A; Target 5. Low affinity immunoglobulin gamma Fc region receptor II-a; Target 6. Low affinity immunoglobulin gamma Fc region receptor II-b; Target 7. Low affinity immunoglobulin gamma Fc region receptor II-c; Target 8. Lymphotoxin-alpha; Target 9. Low affinity immunoglobulin gamma Fc region receptor III-B; Target 10. Complement C1s subcomponent; Target 11. Complement C1r subcomponent; Target 12. Complement C1q subcomponent subunit A; Target 13. Complement C1q subcomponent subunit B; Target 14. Complement C1q subcomponent subunit C